What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Gene
His primary scientific interests are in Multiple sclerosis, Internal medicine, Expanded Disability Status Scale, Physical therapy and Natalizumab.
His Multiple sclerosis study is concerned with the larger field of Immunology.
His Expanded Disability Status Scale course of study focuses on Pregnancy and Young adult and Interquartile range.
His Physical therapy study also includes
- Severity of illness which intersects with area such as Cohort study,
- Cross-sectional study that intertwine with fields like Disease, Predictive value of tests and Bone density.
As a part of the same scientific study, Helmut Butzkueven usually deals with the Natalizumab, concentrating on Fingolimod and frequently concerns with Alemtuzumab and Lower risk.
His Genome-wide association study research is multidisciplinary, relying on both Polymorphism, Genetic predisposition and Genetic association.
His most cited work include:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Multiple sclerosis, Internal medicine, Natalizumab, Expanded Disability Status Scale and Fingolimod.
His Multiple sclerosis study deals with the bigger picture of Immunology.
His work on Oncology expands to the thematically related Internal medicine.
His research integrates issues of Alemtuzumab, Adverse effect, Discontinuation and Relapsing remitting in his study of Natalizumab.
His study in Expanded Disability Status Scale is interdisciplinary in nature, drawing from both Prospective cohort study and Incidence.
The concepts of his Cohort study study are interwoven with issues in Severity of illness and Confidence interval.
He most often published in these fields:
- Multiple sclerosis (105.77%)
- Internal medicine (58.45%)
- Natalizumab (27.04%)
What were the highlights of his more recent work (between 2018-2021)?
- Multiple sclerosis (105.77%)
- Internal medicine (58.45%)
- Natalizumab (27.04%)
In recent papers he was focusing on the following fields of study:
His main research concerns Multiple sclerosis, Internal medicine, Natalizumab, Cohort and Cohort study.
Many of his research projects under Multiple sclerosis are closely connected to Clinical neurology with Clinical neurology, tying the diverse disciplines of science together.
His work focuses on many connections between Internal medicine and other disciplines, such as Oncology, that overlap with his field of interest in Relapsing remitting.
His Natalizumab research includes themes of Fingolimod, Adverse effect, Discontinuation and Ocrelizumab.
Helmut Butzkueven focuses mostly in the field of Cohort, narrowing it down to matters related to Proportional hazards model and, in some cases, Clinically isolated syndrome and Gestation.
His Cohort study research incorporates themes from Pregnancy, Alemtuzumab, Quartile and Obstetrics.
Between 2018 and 2021, his most popular works were:
- Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis (108 citations)
- Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis (108 citations)
- Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis (108 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Helmut Butzkueven focuses on Multiple sclerosis, Cohort study, Internal medicine, Natalizumab and Fingolimod.
Multiple sclerosis connects with themes related to Family medicine in his study.
The study incorporates disciplines such as Pregnancy, Disease and Obstetrics in addition to Cohort study.
His research investigates the connection between Internal medicine and topics such as Expanded Disability Status Scale that intersect with problems in Confidence interval and Hazard ratio.
His research in Natalizumab intersects with topics in Observational study, Alemtuzumab and Glatiramer acetate.
His studies deal with areas such as Lower risk and Neurology as well as Glatiramer acetate.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
